Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 94

Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, "Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Liver Cancer Diagnostic Tests under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Liver Cancer Diagnostic Tests Overview 9
3 Products under Development 10
3.1 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 10
3.2 Liver Cancer Diagnostic Tests - Pipeline Products by Territory 11
3.3 Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 12
3.4 Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 13
4 Liver Cancer Diagnostic Tests - Pipeline Products under Development by Companies 14
4.1 Liver Cancer Companies - Pipeline Products by Stage of Development 14
4.2 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 16
5 Liver Cancer Diagnostic Tests Companies and Product Overview 18
5.1 Abbott Diagnostics Company Overview 18
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18
5.2 Abcodia Ltd. Company Overview 23
5.2.1 Abcodia Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23
5.3 AXO Science S.A.S. Company Overview 24
5.3.1 AXO Science S.A.S. Pipeline Products & Ongoing Clinical Trials Overview 24
5.4 BioMark Technologies Inc. Company Overview 27
5.4.1 BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
5.5 China Sky One Medical, Inc. Company Overview 28
5.5.1 China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
5.6 Digna Biotech, S.L. Company Overview 29
5.6.1 Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview 29
5.7 Drexel University Company Overview 31
5.7.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview 31
5.8 German Cancer Research Center Company Overview 33
5.8.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 33
5.9 Glycotest, Inc. Company Overview 34
5.9.1 Glycotest, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
5.10 Imperial College London Company Overview 35
5.10.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 35
5.11 IntegraGen SA Company Overview 36
5.11.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 36
5.12 Matrix-Bio, Inc. Company Overview 38
5.12.1 Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
5.13 NanoString Technologies, Inc. Company Overview 40
5.13.1 NanoString Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
5.14 National Cancer Institute Company Overview 42
5.14.1 National Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview 42
5.15 Oncimmune (USA) LLC Company Overview 44
5.15.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44
5.16 Orion Genomics LLC Company Overview 45
5.16.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45
5.17 PleX Diagnostics Company Overview 46
5.17.1 PleX Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 46
5.18 ProMIS Neurosciences Inc. Company Overview 47
5.18.1 ProMIS Neurosciences Inc. Pipeline Products & Ongoing Clinical Trials Overview 47
5.19 Proplex Technologies, Llc Company Overview 49
5.19.1 Proplex Technologies, Llc Pipeline Products & Ongoing Clinical Trials Overview 49
5.20 Proteome Sciences Plc Company Overview 50
5.20.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 50
5.21 Roche Diagnostics International Ltd. Company Overview 52
5.21.1 Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview 52
5.22 TrovaGene, Inc. Company Overview 53
5.22.1 TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53
5.23 University of Rochester Company Overview 55
5.23.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 55
5.24 Ventana Medical Systems, Inc. Company Overview 56
5.24.1 Ventana Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
5.25 Viomics Inc. Company Overview 57
5.25.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 57
5.26 XEPTAGEN SpA Company Overview 58
5.26.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 58
5.27 Xiamen Zeesan Biotech Co.,Ltd Company Overview 63
5.27.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 63
6 Liver Cancer Diagnostic Tests - Recent Developments 64
6.1 Aug 12, 2016: ProMIS Neurosciences Announces Second Quarter 2016 Results 64
6.2 Aug 09, 2016: Blueprint Medicines Reports Second Quarter 2016 Financial Results 65
6.3 Aug 04, 2016: Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments 66
6.4 Aug 04, 2016: PerkinElmer Announces Financial Results for the Second Quarter of 2016 67
6.5 Aug 03, 2016: NanoString Technologies Releases Operating Results for Second Quarter of 2016 68
6.6 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results 69
6.7 Jul 27, 2016: PerkinElmer Elects Frank Witney to Board of Directors 74
6.8 Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia 74
6.9 Jul 12, 2016: PerkinElmer Raises USD552.3 Million in Public Offering of 1.875% Senior Notes Due 2026 75
6.10 Jul 07, 2016: IntegraGen reports strong revenue growth during first half of 2016 76
6.11 Jul 04, 2016: Oncimmune Enters into Research Agreement with Egybiotech and Aarhus University Hospital 76
6.12 Jun 27, 2016: ProMIS Neurosciences Raises USD0.8 Million in Private Placement of Units 76
6.13 Jun 23, 2016: Oncimmune Appoints Julian Hirst as Non-Executive Director 77
6.14 Jun 16, 2016: Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts 77
6.15 Jun 02, 2016: NanoString Technologies Highlights Advances in Precision Oncology and Immunotherapy at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) 78
6.16 Jun 01, 2016: Royal Philips Enters into Research Agreement with Yale School of Medicine 81
6.17 Jun 01, 2016: Proteome Sciences Announces CEO Appointment 81
6.18 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 82
6.19 May 31, 2016: Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 82
6.20 May 31, 2016: Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 83
6.21 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 83
6.22 May 31, 2016: Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 84
6.23 May 11, 2016: ProMIS Neurosciences announces first quarter 2016 results 84
6.24 May 10, 2016: Trovagene Announces First Quarter 2016 Financial Results 85
6.25 May 10, 2016: Blueprint Medicines Reports First Quarter 2016 Financial Results 86
6.26 Apr 27, 2016: A.G. Schneiderman Announces Multistate And Federal Settlement With Wyeth And Pfizer For $784.6m To Resolve Allegations Of Underpaying Rebates Owed Through The Medicaid Drug Rebate Program 88
6.27 Mar 07, 2016: Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems 89
6.28 Dec 02, 2015: Surefire Medical Raises USD15 Million in Series C Financing 89
6.29 Oct 27, 2015: Simple blood test measures risk of liver cancer 89
6.30 Sep 21, 2015: Veran Medical Raises USD30.6 Million in Venture Financing 90
6.31 Sep 09, 2015: Quirem Medical Raises Funds through Private Placement of Shares 90
7 Appendix 91
7.1 Methodology 91
7.2 About GlobalData 93
7.3 Contact Us 94
7.4 Disclaimer 94

1.1 List of Tables
Table 1: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 10
Table 2: Liver Cancer Diagnostic Tests - Pipeline Products by Territory 11
Table 3: Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 12
Table 4: Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 13
Table 5: Liver Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 14
Table 6: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 16
Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18
Table 8: ARCHITECT c16000 System - PIVKA Assay - Product Status 18
Table 9: ARCHITECT c16000 System - PIVKA Assay - Product Description 19
Table 10: ARCHITECT c4000 System - PIVKA Assay - Product Status 19
Table 11: ARCHITECT c4000 System - PIVKA Assay - Product Description 19
Table 12: ARCHITECT c8000 System - PIVKA Assay - Product Status 20
Table 13: ARCHITECT c8000 System - PIVKA Assay - Product Description 20
Table 14: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Status 20
Table 15: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Description 21
Table 16: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Status 21
Table 17: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Description 21
Table 18: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Status 22
Table 19: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Description 22
Table 20: Abcodia Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23
Table 21: Biomarker Test - Liver Cancer - Product Status 23
Table 22: Biomarker Test - Liver Cancer - Product Description 23
Table 23: AXO Science S.A.S. Pipeline Products & Ongoing Clinical Trials Overview 24
Table 24: Multiplexed Detection - Des-Carboxy Prothrombin - Product Status 24
Table 25: Multiplexed Detection - Des-Carboxy Prothrombin - Product Description 25
Table 26: Multiplexed Detection - Matrix metalloproteinase 1 - Product Status 25
Table 27: Multiplexed Detection - Matrix metalloproteinase 1 - Product Description 25
Table 28: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Status 26
Table 29: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Description 26
Table 30: BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
Table 31: Biomarker Assay - Hepatocellular Cancer - Product Status 27
Table 32: Biomarker Assay - Hepatocellular Cancer - Product Description 27
Table 33: China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
Table 34: Diagnostic Kit - Liver Cancer - Product Status 28
Table 35: Diagnostic Kit - Liver Cancer - Product Description 28
Table 36: Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview 29
Table 37: HCC Molecular Marker Assay - Product Status 29
Table 38: HCC Molecular Marker Assay - Product Description 29
Table 39: Oxidated APO-A1 Assay - Product Status 30
Table 40: Oxidated APO-A1 Assay - Product Description 30
Table 41: Drexel University Pipeline Products & Ongoing Clinical Trials Overview 31
Table 42: Diagnostic Test - Liver Cancer - Product Status 31
Table 43: Diagnostic Test - Liver Cancer - Product Description 31
Table 44: Glycan-Based Biomarker Assay - Liver Cancer - Product Status 32
Table 45: Glycan-Based Biomarker Assay - Liver Cancer - Product Description 32
Table 46: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 33
Table 47: RAGE Based Diagnostic Assay - Liver Cancer - Product Status 33
Table 48: RAGE Based Diagnostic Assay - Liver Cancer - Product Description 33
Table 49: Glycotest, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
Table 50: Diagnostic Test - Liver Cancer - Product Status 34
Table 51: Diagnostic Test - Liver Cancer - Product Description 34
Table 52: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 35
Table 53: Diagnostic Assay - HCC - Product Status 35
Table 54: Diagnostic Assay - HCC - Product Description 35
Table 55: IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 36
Table 56: CLIA Test - Hepatocellular Carcinoma - Product Status 36
Table 57: CLIA Test - Hepatocellular Carcinoma - Product Description 37
Table 58: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
Table 59: VeraMarker LCS (Liver Cancer Screening) Test - Product Status 38
Table 60: VeraMarker LCS (Liver Cancer Screening) Test - Product Description 38
Table 61: VeraMarker Liver Cancer Screening Test - Hepatitis - Product Status 39
Table 62: VeraMarker Liver Cancer Screening Test - Hepatitis - Product Description 39
Table 63: NanoString Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
Table 64: In Vitro Diagnostic Assay - HCC Gene Signature - Product Status 40
Table 65: In Vitro Diagnostic Assay - HCC Gene Signature - Product Description 41
Table 66: National Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview 42
Table 67: HCC Gene Signature Diagnostic Test - Product Status 42
Table 68: HCC Gene Signature Diagnostic Test - Product Description 42
Table 69: HCC Gene Signature Prognostic Test - Product Status 43
Table 70: HCC Gene Signature Prognostic Test - Product Description 43
Table 71: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44
Table 72: EarlyCDT - Liver Cancer - Product Status 44
Table 73: EarlyCDT - Liver Cancer - Product Description 44
Table 74: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45
Table 75: Diagnostic Assay - Liver Cancer - Product Status 45
Table 76: Diagnostic Assay - Liver Cancer - Product Description 45
Table 77: PleX Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 46
Table 78: HCCpleX - Product Status 46
Table 79: HCCpleX - Product Description 46
Table 80: ProMIS Neurosciences Inc. Pipeline Products & Ongoing Clinical Trials Overview 47
Table 81: Screening Test - Liver Cancer - Product Status 47
Table 82: Screening Test - Liver Cancer - Product Description 48
Table 83: Proplex Technologies, Llc Pipeline Products & Ongoing Clinical Trials Overview 49
Table 84: Biomarker Diagnostic Test - Liver Cancer - Product Status 49
Table 85: Biomarker Diagnostic Test - Liver Cancer - Product Description 49
Table 86: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 50
Table 87: Biomarker Assay - Liver Cancer - Product Status 50
Table 88: Biomarker Assay - Liver Cancer - Product Description 51
Table 89: Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview 52
Table 90: Glypican-3 MAb Companion Diagnostic Test - Product Status 52
Table 91: Glypican-3 MAb Companion Diagnostic Test - Product Description 52
Table 92: TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53
Table 93: Diagnostic Test - Liver Cancer - Product Status 53
Table 94: Diagnostic Test - Liver Cancer - Product Description 54
Table 95: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 55
Table 96: Biomarker Test - HCC - Product Status 55
Table 97: Biomarker Test - HCC - Product Description 55
Table 98: Ventana Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
Table 99: BLU-554 Companion Diagnostic Assay - Hepatocellular Carcinoma - Product Status 56
Table 100: BLU-554 Companion Diagnostic Assay - Hepatocellular Carcinoma - Product Description 56
Table 101: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 57
Table 102: Diagnostic Assay - Liver Cancer - Product Status 57
Table 103: Diagnostic Assay - Liver Cancer - Product Description 57
Table 104: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 58
Table 105: compleXima HCC Biochip - Liver Cancer - Product Status 58
Table 106: compleXima HCC Biochip - Liver Cancer - Product Description 59
Table 107: DCP-IgM Kit - Liver Cancer - Product Status 59
Table 108: DCP-IgM Kit - Liver Cancer - Product Description 59
Table 109: GPC3-IgM Kit - Liver Cancer - Product Status 60
Table 110: GPC3-IgM Kit - Liver Cancer - Product Description 60
Table 111: Osteopontin-IgM Kit - Liver Cancer - Product Status 60
Table 112: Osteopontin-IgM Kit - Liver Cancer - Product Description 61
Table 113: Survivin-IgM Kit - Liver Cancer - Product Status 61
Table 114: Survivin-IgM Kit - Liver Cancer - Product Description 61
Table 115: VEGF-IgM Kit - Liver Cancer - Product Status 62
Table 116: VEGF-IgM Kit - Liver Cancer - Product Description 62
Table 117: Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 63
Table 118: Theranostic - Liver Cancer Metastasis - Product Status 63
Table 119: Theranostic - Liver Cancer Metastasis - Product Description 63
Table 120: Glossary 92

1.2 List of Figures
Figure 1: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 10
Figure 2: Liver Cancer Diagnostic Tests - Pipeline Products by Territory 11
Figure 3: Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 12
Figure 4: Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 13
  • Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, qPCR, In-situ Hybridization, Microarray)- Forecast to 2021
    Published: 06-Dec-2016        Price: US 5650 Onwards        Pages: 157
    The global Cancer/Tumor Profiling market is poised to reach USD 61.87 billion by 2021 from USD 25.82 billion in 2016, at a CAGR of 19.1% from 2016 to 2021. Increasing number of cancer cases across the globe, the increasing utility of biomarkers, and availability of funding for cancer research are the major factors driving the growth of the global Cancer/Tumor Profiling market. In recent years, the Asia-Pacific market for cancer/tumor profiling has witnessed significant growth due to t......
  • Europe Cancer Diagnostics Market 2017-2021: France, Germany, Italy, Spain, UK--Opportunities for Instrument and Reagent Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
    Published: 02-Dec-2016        Price: US 19700 Onwards        Pages: 820
    Complete report $19,700.DataPack (test volumes, sales forecasts, supplier shares) $12,800.SummaryThis comprehensive five-country report contains 820 pages, 320 tables, and presents analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging tests; ana......
  • Europe Pap Smear/Papillomavirus (HPV) Diagnostics Market: France, Germany, Italy, Spain, UK--Opportunities for Instrument and Reagent Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
    Published: 02-Dec-2016        Price: US 2850 Onwards        Pages: 240
    Complete report $2,850.  DataPack (test volumes, sales forecasts) $1,850.This report presents a detailed analysis of the Pap Smear/HPV testing market in Europe (France, Germany, Italy, Spain, UK), including clinical significance and current laboratory practice; as well as five-year test volume and sales forecasts by country and market segment.The report examines market applications of DNA probes, biochips/microarrays, monoclonal antibo......
  • Leukemia Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
    Published: 01-Dec-2016        Price: US 4000 Onwards        Pages: 157
    GlobalData's Medical Devices sector report, "Leukemia Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Leukemia Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, whic......
  • Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
    Published: 01-Dec-2016        Price: US 4000 Onwards        Pages: 175
    GlobalData's Medical Devices sector report, "Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Pancreatic Cancer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials......
  • Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
    Published: 01-Dec-2016        Price: US 4000 Onwards        Pages: 470
    GlobalData's Medical Devices sector report, "Prostate Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" provides an overview of Prostate Cancer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in ......
  • Global Cancer Testing Product Sales Market Report 2016
    Published: 30-Nov-2016        Price: US 4000 Onwards        Pages: 109
    Notes: Sales, means the sales volume of Cancer Testing Product Revenue, means the sales value of Cancer Testing Product This report studies sales (consumption) of Cancer Testing Product in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Abbott Diagnostics - Agilent Technologies - Beckman Cou......
  • 2016-2021 France Hospital Cancer Diagnostics Market Forecasts: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation Review
    Published: 28-Nov-2016        Price: US 3850 Onwards        Pages: 533
    This new report from VPGMarketResearch contains 533 pages, 43 tables, and presents a comprehensive analysis of the French hospital cancer diagnostics market, including: Major issues pertaining to the French hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.Mortality statistics and scientific views on the etiology of major types o......
  • 2016-2021 Germany Hospital Cancer Diagnostics Market Forecasts: Supplier Shares, Competitive Landscape, Innovative Technologies, Instrumentation Review
    Published: 28-Nov-2016        Price: US 3850 Onwards        Pages: 533
    This new report from VPGMarketResearch contains 533 pages, 40 tables, and presents a comprehensive analysis of the German hospital cancer diagnostics market, including: Major issues pertaining to the German hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of ma......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs